Giles T D
Tulane University School of Medicine, Veterans Administration Medical Center, New Orleans, Louisiana.
J Hum Hypertens. 1989 Jun;3 Suppl 1:83-7.
In a series of studies, lisinopril, a new, once-daily, non-sulphydryl-containing ACE inhibitor, has been evaluated for the treatment of congestive heart failure (CHF). Lisinopril significantly improved exercise duration, left ventricular ejection fraction (LVEF) and the clinical signs and symptoms of CHF when compared with placebo in a 12-week prospective, randomised, double-blind trial involving 130 patients (NYHA Class II-IV) who were also receiving digitalis and diuretics. In another study involving 10 patients with CHF, lisinopril was found to increase maximal oxygen uptake. Lisinopril has also been compared with captopril in a 12-week randomised, double-blind, parallel trial in 189 patients with CHF (Class II-IV) on digoxin and diuretics. Both lisinopril and captopril increased treadmill exercise times. However, lisinopril was equally effective in patients with renal impairment whereas captopril was not. Also, lisinopril, but not captopril, improved LVEF. In all studies, lisinopril was well tolerated in a manner similar to captopril. Lisinopril produces more frequent increases in serum creatinine than captopril, but these changes are rarely of significant consequence. These results confirm those of previous studies, from which it is concluded that lisinopril is an important addition to the ACE inhibitor class for the treatment of CHF.
在一系列研究中，对一种新型的每日服用一次的不含巯基的血管紧张素转换酶（ACE）抑制剂赖诺普利进行了充血性心力衰竭（CHF）治疗效果的评估。在一项为期12周的前瞻性、随机、双盲试验中，对130例（纽约心脏协会心功能II - IV级）同时服用洋地黄和利尿剂的患者进行研究，结果显示与安慰剂相比，赖诺普利显著改善了运动持续时间、左心室射血分数（LVEF）以及CHF的临床体征和症状。在另一项涉及10例CHF患者的研究中，发现赖诺普利可增加最大摄氧量。在一项针对189例服用地高辛和利尿剂的CHF（心功能II - IV级）患者进行的为期12周的随机、双盲、平行试验中，还将赖诺普利与卡托普利进行了比较。赖诺普利和卡托普利均增加了跑步机运动时间。然而，赖诺普利对肾功能损害患者同样有效，而卡托普利则不然。此外，赖诺普利改善了LVEF，而卡托普利则没有。在所有研究中，赖诺普利的耐受性与卡托普利相似。赖诺普利比卡托普利更频繁地导致血清肌酐升高，但这些变化很少产生重大影响。这些结果证实了先前研究的结果，由此得出结论，赖诺普利是ACE抑制剂类药物中治疗CHF的重要补充药物。
